EnCoate encoate.com


Public lists: Pharma Startups (4743)

EnCoate develops , cost effective, food-grade biopolymer technologies. These simple biopolymers have broad application in extending the shelf-life of food, pharmaceutical and agricultural products (such as probiotics) at ambient temperatures.

EnCoate develops , cost effective, food-grade biopolymer technologies. These simple biopolymers have broad application in extending the shelf-life of food, pharmaceutical and agricultural products (such as probiotics) at ambient temperatures.

Company (Alive / Active)

Phone: 649-306-8892

Fax: 64 9 306 8889

PO Box 5636
Wellesley Street
1141
New Zealand

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
EnCoate $0M Apr 19, 2019
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related EnCoate Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

NeuroGenomeX

Madison, Wisconsin, United States
Alive / ActiveNeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in...Show allLogin to see details

Axela Biosensors

Toronto, Ontario, Canada
Alive / ActiveAxela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)